<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042093</url>
  </required_header>
  <id_info>
    <org_study_id>1113723</org_study_id>
    <nct_id>NCT01042093</nct_id>
  </id_info>
  <brief_title>Efficacy of Multimodal Perioperative Analgesia With Periarticular Drug Injection in Total Knee Arthroplasty(TKA)</brief_title>
  <official_title>Efficacy of Multimodal Perioperative Analgesia Protocol With Periarticular Drug Injection in Total Knee Arthroplasty: A Randomized, Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Towson Orthopaedic Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Towson Orthopaedic Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare different medication combinations used in a
      periarticular injection after total knee replacement surgery(TKR). A periarticular injection
      is an injection that is given into the tissues surrounding the knee joint. The injection is
      given while the patient is still in surgery.

      The study will compare the level of pain management, length of hospital stay, range of motion
      and side effects from subjects receiving one of four different combinations of medication in
      a periarticular injection. The medications used in the injections are approved medications
      routinely used for pain management.

      Approximately 160 subjects will participate in this study. The surgeon, study personnel, and
      patients will be blinded to the combination of medications each patient receives. The
      pharmacist will prepare the 4 different combinations of medications, randomize each patient
      to the particular combination of medications, and maintain the study drug documentation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data Collection:

      Data will be collected from the patient's pre-operative office visit, up to six weeks
      post-operatively.

      Variables

      Pre-operative Collection:

        -  Vital signs

        -  Hb/Hct

        -  Age

        -  Sex

        -  BMI

        -  WOMAC Score - Screen Failure at 36 or 12

        -  Visual Analog Scale (VAS)

      Intra-operative Collection:

        -  Duration of surgery

        -  Tourniquet time

        -  Time of periarticular injection

      Post-operative Collection:

        -  Pain Scores in the inpatient post-anesthesia care unit (PACU) using the 1- to 10- point
           Visual Analog Scale (VAS) an admission to unit, 1 hour, 2 hour, and on discharge.

        -  VAS pain scores every 8 hours on the Orthopaedic floor

        -  Use of supplementary narcotics

        -  Use of anti-emetics

        -  Serious Adverse Events (SAE) including deep vein thrombosis (DVT) formation, pulmonary
           embolism (PE), myocardial infarct or other serious cardiac event, excessive bleeding

        -  Length of hospital stay

        -  Requirement for inpatient rehabilitation versus discharge home

        -  Hours/Days to straight leg raise -POD 1, 2, 3 by MD on rounds.

        -  Days to independent ambulation

        -  Hemoglobin and Hematocrit levels on post-operative days one and two

        -  Presence/Absence of Bowel/Bladder Function

      Data to be Collected by Physical Therapist: POD 1, 2, 3, Numerical Rating Scale (NRS) Pain
      with Ambulation

        -  Use of Assisted Devices

        -  Distance walked

        -  Range of Motion(ROM) (using Goniometer)- active and passive.

      Treatment Periods Screening Visit Day 0 - Day of surgery Visit Day 1, 2, 3 (Post-operative
      days 1, 2, and 3) 6 Week visit in Office
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Scale (NRS) Pain Scores During Hospitalization.</measure>
    <time_frame>2 days after surgery</time_frame>
    <description>Patient pain was assessed during hospitalization using the VAS Pain Scale, a numerical rating scale ranging from 0 (no pain) to 10 (severe pain). A lower score represents a better outcome. Pain was assessed preoperatively, 1 hour postoperatively in the post anesthesia unit, and then every 8 hours on the Orthopedic inpatient unit, for a duration of 2 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Narcotic Consumption During Hospitalization</measure>
    <time_frame>4 days</time_frame>
    <description>A variety of pain medications were used after surgery to keep patients comfortable. Narcotic use was recorded as morphine equivalents. We report the mean narcotic consumption for each group for the day of surgery as well as post operative day 1,2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Society Pain Scores at 6 Week Follow-up Appointment</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>Patients were assessed for pain at their 6 week follow-up appointment using the Knee Society Rating Scale. Using this scale patients are given a pain score ranging from 0 (severe pain) to 50 (No Pain). This is determined as follows: No pain/50 points, Mild or occasional pain/45 points, pain with stairs only/40 points, pain with walking and stairs/30 points, Moderate/occasional pain/ 20 points,continual pain/10 points, severe pain/0 points. We report the mean score for each group. A higher score represents a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Osteoarthritis,Knee</condition>
  <arm_group>
    <arm_group_label>ROP/EPI/TOR/CLO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROP/EPI/TOR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROP/EPI/CLO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROP/EPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine 5mg/ml (49.25ml) Epinephrine 1 mg/ml (0.5 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropivacaine 5mg/ml (49.25 ml)</description>
    <arm_group_label>ROP/EPI/TOR/CLO</arm_group_label>
    <arm_group_label>ROP/EPI/TOR</arm_group_label>
    <arm_group_label>ROP/EPI/CLO</arm_group_label>
    <arm_group_label>ROP/EPI</arm_group_label>
    <other_name>periarticular injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toradol</intervention_name>
    <description>Toradol 30mg/ml (1 ml)</description>
    <arm_group_label>ROP/EPI/TOR/CLO</arm_group_label>
    <arm_group_label>ROP/EPI/TOR</arm_group_label>
    <other_name>periarticular injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
    <arm_group_label>ROP/EPI/TOR/CLO</arm_group_label>
    <arm_group_label>ROP/EPI/CLO</arm_group_label>
    <other_name>periarticular injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Epinephrine 1 mg/ml (0.5 ml)</description>
    <arm_group_label>ROP/EPI/TOR/CLO</arm_group_label>
    <arm_group_label>ROP/EPI/TOR</arm_group_label>
    <arm_group_label>ROP/EPI/CLO</arm_group_label>
    <arm_group_label>ROP/EPI</arm_group_label>
    <other_name>periarticular injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and Women aged 30 to 85 years

          2. Voluntary, written informed consent given to participate in this clinical
             investigation

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Presence of allergies or contraindication to any medications indicated in the study

          3. Contraindication to or failure of spinal anesthesia

          4. Known drug or alcohol abuse or psychologic disorder that could affect follow-up care
             or treatment outcomes

          5. Patients with a diagnosis of inflammatory arthritis

          6. Previous major bone surgery in the operative knee

          7. Simultaneous, bilateral TKRs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David F. Dalury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Towson Orthpaedic Associates</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <results_first_submitted>June 20, 2013</results_first_submitted>
  <results_first_submitted_qc>September 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2013</results_first_posted>
  <last_update_submitted>September 5, 2013</last_update_submitted>
  <last_update_submitted_qc>September 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Towson Orthopaedic Associates</investigator_affiliation>
    <investigator_full_name>David F. Dalury, MD</investigator_full_name>
    <investigator_title>Orthopaedic Surgeon</investigator_title>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>periarticular</keyword>
  <keyword>arthroplasty</keyword>
  <keyword>pain management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients scheduled for Total Knee Replacement (TKR), by the investigator and considered suitable for participation,were recruited for the study from Jan 2010 through June 2011.</recruitment_details>
      <pre_assignment_details>Before assignment to groups all participants were screened for certain exclusion criteria including; pregnant/lactating women, allergies/contraindications to study medications/spinal anesthesia, drug/alcohol abuse, psychologic disorder, diagnosis of inflammatory arthritis, previous major surgery to operative knee, and simultaneous bilateral TKR's.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ROP/EPI/TOR/CLO</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
        </group>
        <group group_id="P2">
          <title>REP/EPI/TOR</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)</description>
        </group>
        <group group_id="P3">
          <title>REP/EPI/CLO</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
        </group>
        <group group_id="P4">
          <title>REP/EPI</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ROP/EPI/TOR/CLO</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
        </group>
        <group group_id="B2">
          <title>ROP/EPI/TOR</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)</description>
        </group>
        <group group_id="B3">
          <title>ROP/EPI/CLO</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
        </group>
        <group group_id="B4">
          <title>ROP/EPI</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.74" spread="8.07"/>
                    <measurement group_id="B2" value="66.29" spread="8.20"/>
                    <measurement group_id="B3" value="68.26" spread="7.47"/>
                    <measurement group_id="B4" value="69.25" spread="8.67"/>
                    <measurement group_id="B5" value="67.64" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numerical Rating Scale (NRS) Pain Scores During Hospitalization.</title>
        <description>Patient pain was assessed during hospitalization using the VAS Pain Scale, a numerical rating scale ranging from 0 (no pain) to 10 (severe pain). A lower score represents a better outcome. Pain was assessed preoperatively, 1 hour postoperatively in the post anesthesia unit, and then every 8 hours on the Orthopedic inpatient unit, for a duration of 2 days.</description>
        <time_frame>2 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ROP/EPI/TOR/CLO</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
          </group>
          <group group_id="O2">
            <title>ROP/EPI/TOR</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)</description>
          </group>
          <group group_id="O3">
            <title>ROP/EPI/CLO</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
          </group>
          <group group_id="O4">
            <title>ROP/EPI</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Rating Scale (NRS) Pain Scores During Hospitalization.</title>
          <description>Patient pain was assessed during hospitalization using the VAS Pain Scale, a numerical rating scale ranging from 0 (no pain) to 10 (severe pain). A lower score represents a better outcome. Pain was assessed preoperatively, 1 hour postoperatively in the post anesthesia unit, and then every 8 hours on the Orthopedic inpatient unit, for a duration of 2 days.</description>
          <units>scores on a scale 0-10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vas Pain Scale - 1 Hour Post Op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.74"/>
                    <measurement group_id="O2" value="1.90" spread="1.04"/>
                    <measurement group_id="O3" value="2.67" spread="3.06"/>
                    <measurement group_id="O4" value="1.60" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vas Pain Scale - 8 Hour Post Op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="1.54"/>
                    <measurement group_id="O2" value="1.52" spread="1.56"/>
                    <measurement group_id="O3" value="3.93" spread="2.57"/>
                    <measurement group_id="O4" value="2.82" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vas Pain Scale - 16 Hour Post Op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="1.69"/>
                    <measurement group_id="O2" value="2.22" spread="2.36"/>
                    <measurement group_id="O3" value="2.75" spread="2.36"/>
                    <measurement group_id="O4" value="2.41" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vas Pain Scale - 24 Hour Post Op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="2.06"/>
                    <measurement group_id="O2" value="2.56" spread="1.76"/>
                    <measurement group_id="O3" value="3.63" spread="2.86"/>
                    <measurement group_id="O4" value="2.96" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vas Pain Scale - 32 Hour Post Op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="2.13"/>
                    <measurement group_id="O2" value="2.66" spread="2.13"/>
                    <measurement group_id="O3" value="3.62" spread="2.19"/>
                    <measurement group_id="O4" value="3.13" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vas Pain Scale - 40 Hour Post Op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="2.20"/>
                    <measurement group_id="O2" value="2.35" spread="2.31"/>
                    <measurement group_id="O3" value="3.28" spread="2.49"/>
                    <measurement group_id="O4" value="2.80" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vas Pain Scale - 48 Hour Post Op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="2.25"/>
                    <measurement group_id="O2" value="1.97" spread="1.72"/>
                    <measurement group_id="O3" value="2.56" spread="2.20"/>
                    <measurement group_id="O4" value="2.11" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vas Pain Scale Preoperatively</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="2.07"/>
                    <measurement group_id="O2" value="2.47" spread="2.25"/>
                    <measurement group_id="O3" value="2.43" spread="2.40"/>
                    <measurement group_id="O4" value="2.13" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Consumption During Hospitalization</title>
        <description>A variety of pain medications were used after surgery to keep patients comfortable. Narcotic use was recorded as morphine equivalents. We report the mean narcotic consumption for each group for the day of surgery as well as post operative day 1,2, and 3.</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ROP/EPI/TOR/CLO</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
          </group>
          <group group_id="O2">
            <title>ROP/EPI/TOR</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)</description>
          </group>
          <group group_id="O3">
            <title>ROP/EPI/CLO</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
          </group>
          <group group_id="O4">
            <title>ROP/EPI</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Consumption During Hospitalization</title>
          <description>A variety of pain medications were used after surgery to keep patients comfortable. Narcotic use was recorded as morphine equivalents. We report the mean narcotic consumption for each group for the day of surgery as well as post operative day 1,2, and 3.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morphine Equivalent Day of Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.92" spread="22.29"/>
                    <measurement group_id="O2" value="43.09" spread="25.33"/>
                    <measurement group_id="O3" value="55.20" spread="28.00"/>
                    <measurement group_id="O4" value="52.50" spread="27.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morphine Equivalent Post Operative Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.54" spread="29.14"/>
                    <measurement group_id="O2" value="47.95" spread="35.89"/>
                    <measurement group_id="O3" value="64.61" spread="41.71"/>
                    <measurement group_id="O4" value="51.08" spread="39.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morphine Equivalent Post Operative Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.71" spread="29.67"/>
                    <measurement group_id="O2" value="42.69" spread="37.28"/>
                    <measurement group_id="O3" value="50.07" spread="44.11"/>
                    <measurement group_id="O4" value="36.76" spread="35.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morphine Equivalent Post Operative Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.45" spread="19.88"/>
                    <measurement group_id="O2" value="18.72" spread="20.73"/>
                    <measurement group_id="O3" value="21.97" spread="22.38"/>
                    <measurement group_id="O4" value="15.54" spread="21.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Knee Society Pain Scores at 6 Week Follow-up Appointment</title>
        <description>Patients were assessed for pain at their 6 week follow-up appointment using the Knee Society Rating Scale. Using this scale patients are given a pain score ranging from 0 (severe pain) to 50 (No Pain). This is determined as follows: No pain/50 points, Mild or occasional pain/45 points, pain with stairs only/40 points, pain with walking and stairs/30 points, Moderate/occasional pain/ 20 points,continual pain/10 points, severe pain/0 points. We report the mean score for each group. A higher score represents a better outcome.</description>
        <time_frame>6 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ROP/EPI/TOR/CLO</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
          </group>
          <group group_id="O2">
            <title>REP/EPI/TOR</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)</description>
          </group>
          <group group_id="O3">
            <title>REP/EPI/CLO</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
          </group>
          <group group_id="O4">
            <title>REP/EPI</title>
            <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Society Pain Scores at 6 Week Follow-up Appointment</title>
          <description>Patients were assessed for pain at their 6 week follow-up appointment using the Knee Society Rating Scale. Using this scale patients are given a pain score ranging from 0 (severe pain) to 50 (No Pain). This is determined as follows: No pain/50 points, Mild or occasional pain/45 points, pain with stairs only/40 points, pain with walking and stairs/30 points, Moderate/occasional pain/ 20 points,continual pain/10 points, severe pain/0 points. We report the mean score for each group. A higher score represents a better outcome.</description>
          <units>Scores on a scale 0-50</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="30" upper_limit="50"/>
                    <measurement group_id="O2" value="43" lower_limit="10" upper_limit="50"/>
                    <measurement group_id="O3" value="45" lower_limit="10" upper_limit="50"/>
                    <measurement group_id="O4" value="45" lower_limit="10" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ROP/EPI/TOR/CLO</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
        </group>
        <group group_id="E2">
          <title>ROP/EPI/TOR</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)</description>
        </group>
        <group group_id="E3">
          <title>ROP/EPI/CLO</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)</description>
        </group>
        <group group_id="E4">
          <title>ROP/EPI</title>
          <description>Ropivicaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David F. Dalury, MD</name_or_title>
      <organization>Towson Orthopaedic Associates</organization>
      <phone>410-337-7900 ext 1221</phone>
      <email>ddalury@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

